[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nosocomial-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nosocomial-infections":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100612417","evaluation-of-rapid-diagnostic-device-for-the-detection-of-candida-auris-100612417",false,"NCT07253311","Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris","Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris DiagRaMIE C AURIS","DiagRaMIE Caur","Inclusion Criteria:\n\nFrom patients with suspected Candida auris infection:\n\n\\- All isolates from the population that grow on the selective media: Sabouraud-dextrose (40g\u002FL dextrose, 5.0g\u002FL of peptic digest of animal tissue, 5.0 g\u002FL of pancreatic digest of casein, 15.0 g\u002FL of agar and final pH 5.6 ± 0.2) and CHROMagar™ Candida plus (manufactured by CHROMagar™, France). used in the hospital's routine diagnostic process.\n\nFrom patients with suspected Candida auris cutaneous colonization:\n\n\\- All isolates from the population that grow on the selective media: Salt-Sabouraud Dulcitol Broth (SSDB) with chloramphenicol and gentamicin (manufactured by S2 Media, United States), And the media used in the hospital's routine diagnostic process: Sabouraud Dextrose Liquid Medium containing NaCl 10%, chloramphenicol 50 mg\u002FL.\n\nExclusion Criteria:\n\n* NA","ALL","18 Years",{"count":20,"type":21},554,"ESTIMATED","OBSERVATIONAL","\"Candida auris is an emerging fungus that can cause severe infections, particularly in hospitalized patients, and is often resistant to multiple antifungal treatments. Rapid and accurate detection of this pathogen is essential to control its spread in healthcare settings.\n\nThis study aims to evaluate the clinical performance of the NG-Test® Candida auris rapid diagnostic test (RDT), developed by CEA and NG Biotech. The test uses immunochromatography and can detect Candida auris in about 15 minutes. Its results will be compared to the reference method, MALDI-TOF, performed on colonies grown from routine patient samples.\n\nBoth retrospective (using stored isolates) and prospective (using new isolates) evaluations will be conducted. The study will measure the sensitivity and specificity of the test, and also include an assessment of its ease of use by laboratory staff. No additional samples will be collected from patients, and all testing will use de-identified isolates to ensure confidentiality.\"",[25,26,27],"Candida Auris Infection","Candida Auris Colonization","Nosocomial Infections",[29,30,31,32,33,34,35,36,37],"Candida auris","Diagnostic Tests","Routine","Immunochromatography","Microbiological Techniques","Sensitivity and Specificity","Microbial Drug Resistance, Fungal","Infection","Control","RECRUITING","2026-06-22",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":42},"2026-05-25",{"date":46,"type":21},"2026-10-31",{"name":48,"class":49},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100565504","nosocomial-respiratory-virus-infection-100565504","NCT06643039","Nosocomial Respiratory Virus Infection","Hospital-acquired Respiratory Viral Infection: A Prospective Multicenter Study in France","NOSOVIRUS","Inclusion Criteria:\n\n* Adults\\> 18 years old\n* Hospitalized patient or health care professionals presenting an ILI on admission or during the stay, meeting the following definition: fever greater than 37.8° C in the absence of taking antipyretics and\u002For cough or pharyngeal pain.\n* Signed consent form\n\nExclusion Criteria:\n\n* Pregnant, parturient or breastfeeding women\n* individuals deprived of their liberty by a judicial or administrative decision\n* Individuals subject to psychiatric care\n* Individuals admitted to a health or social establishment for purposes other than research\n* Individuals under a legal protection measure (guardianship, curatorship)\n* Individuals not affiliated to a social security insurance",true,{"count":61,"type":21},1000,"INTERVENTIONAL",[64],"NA","Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing mask. However, vaccination remains the major preventive measure.\n\nTo date, data at French national level are insufficient to describe the epidemiology of these infections, including their burden, and the potential protection of patients if vaccination coverage of health care professionals\u002Fpatients is satisfactory. In addition, better understanding of the clinical characteristics of HAVRI will make it possible to identify potential sources of transmission as soon as possible and to implement appropriate hygiene measures.\n\nWe will set up a hospital-based prospective multicenter study in Bordeaux, Paris-Bichat, Dijon and Lyon, involving four inclusion services (geriatrics, internal medicine and transplantation) per hospital.\n\nThe main objective of this study is to calculate the incidence rate of hospital-acquired infections for three respiratory viruses; influenza, SARS-CoV-2 and syncytial respiratory virus (SRV), referred to as HARVI, in participating services.\n\nVolunteered health care professionals or hospitalized patients presenting with influenza-like illness (ILI) at admission or during their stay in the participating centers will be eligible to be enrolled during the two inclusion periods: (mid-October 2024 to mid-April 2025 and mid-October 2025 to mid-April 2026).\n\nFor each patient\u002Fhealth care professional, a nasopharyngeal swab will be collected. A questionnaire including demographic data, medical history, vaccination, and clinical and biological data of the viral episode will also be completed by the study team. Patients tested positive for one of the viruses studied will be considered \"cases\" and patients tested negative as \"controls\".\n\nThe collected data will be pseudonymized before statistical analyses. Statistical analyses will consist of calculating incidence rates, attack rates overall and by causative virus and analysis of factors associated with the occurrence of HARVI.\n\nThe prospective design of the study will optimize the quality of the collected data (ex. consolidate the documentation of both the clinical picture and vaccination in patients and health care professionals by reducing memory bias) and allow to calculate the incidence rates, the crude and adjusted relative risks of HARVI according to the studied factors, and to describe multiple outcomes (hospitalization in intensive care units, death, etc.) based on the causative virus.\n\nThe results of this research project will allow to:\n\n* obtain epidemiological indicators associated with HARVI;\n* estimate the impact of HARVI on the prognosis of patients in hospital;\n* assess the impact of HARVI on the total length of hospital stay;\n* identify risk factors associated with HARVI;\n* use the results as an argument for vaccination in order to increase vaccination coverage of healthcare workers.",[27],[68,69,70,71,72],"Hospital-acquired infection","COVID-19","Influenza","SRV","France","2024-12-09",{"date":75,"type":42},"2024-12-10",{"date":77,"type":42},"2024-12-05",{"date":79,"type":21},"2026-07-05",{"name":81,"class":49},"Hospices Civils de Lyon",4]